Zentiva, a Czechia-based generics pharmaceutical company, announced on Friday that it has received the ESG Transparency Award 2025, presented by German market research organisation EUPD Group at the ESG Summit 2025.
The award aims to recognise companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.
EUPD Group said that Zentiva was awarded the Excellence Level of the ESG Transparency Award for its high degree of clarity, accessibility and transparency in sustainability reporting. This distinction places the company among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz